Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients

Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:January 2016
Contact:David Wang, MD, PhD

Use our guide to learn which trials are right for you!

Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer

The purpose of this study is to demonstrate that orally administered itraconazole, a commonly
used antifungal medication, can inhibit Hedgehog pathway signaling in patients with
esophageal cancer, including adenocarcinoma (EAC) and squamous cell carcinoma (ESCC).

Inclusion Criteria:

• Clinical diagnosis of esophageal cancer, including gastroesophageal junction cancer

Exclusion Criteria:

- Patients unwilling or unable to provide informed consent

- Coagulopathy that precludes safe endoscopic/surgical procedure (platelet count
<100,000/mm3, INR>1.5)

- Esophageal varices

- Comorbidity (e.g. pulmonary, cardiac, renal, or liver disease) that precludes safe
participation in the study

- QTc>450 ms

- LFT's>3xULN

- Pregnancy

- Allergy to itraconazole

- History of symptomatic congestive heart failure
We found this trial at
4500 S. Lancaster Rd.
Dallas, Texas 75216
Phone: 214-857-4237
Dallas VA Medical Center VA North Texas Health Care System (VANTHCS) is a progressive health...
Dallas, TX
Click here to add this to my saved trials